SABS
SAB Biotherapeutics Inc

1,674
Mkt Cap
$189.69M
Volume
527,434.00
52W High
$6.60
52W Low
$1.00
PE Ratio
-1.29
SABS Fundamentals
Price
$4.01
Prev Close
$3.98
Open
$3.82
50D MA
$3.73
Beta
0.75
Avg. Volume
298,775.77
EPS (Annual)
-$3.68
P/B
1.15
Rev/Employee
$20,990.63
Loading...
Loading...
News
all
press releases
SAB Biotherapeutics, Inc. (NASDAQ:SABS) Sees Significant Increase in Short Interest
SAB Biotherapeutics, Inc. (NASDAQ:SABS - Get Free Report) saw a significant growth in short interest in the month of December. As of December 15th, there was short interest totaling 901,471 shares, a...
MarketBeat·21d ago
News Placeholder
More News
News Placeholder
SAB Biotherapeutics, Inc. (NASDAQ:SABS) Given Consensus Rating of "Moderate Buy" by Analysts
Shares of SAB Biotherapeutics, Inc. (NASDAQ:SABS - Get Free Report) have been given an average recommendation of "Moderate Buy" by the six research firms that are currently covering the firm...
MarketBeat·23d ago
News Placeholder
SAB Biotherapeutics, Inc. (NASDAQ:SABS) Given Consensus Recommendation of "Moderate Buy" by Brokerages
Shares of SAB Biotherapeutics, Inc. (NASDAQ:SABS - Get Free Report) have received a consensus recommendation of "Moderate Buy" from the five research firms that are currently covering the company...
MarketBeat·2mo ago
News Placeholder
SAB Biotherapeutics (NASDAQ:SABS) Upgraded by Wall Street Zen to Hold Rating
Wall Street Zen raised SAB Biotherapeutics from a "sell" rating to a "hold" rating in a report on Saturday...
MarketBeat·2mo ago
News Placeholder
SAB Biotherapeutics, Inc. (SABS) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
SAB Biotherapeutics (SABS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks·6mo ago
News Placeholder
Oculis Holding AG (OCS) Reports Q1 Loss, Tops Revenue Estimates
chainwire·9mo ago
<
...
1
>

Latest SABS News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.